Central Nervous System (CNS)An R&D Focus
With years upon years of first-hand experience in advancing the development of the modern medicine and drugs, we know how to make the world healthier!
In CNS, ReHealth is advancing programs to treat critical conditions such as Major Depressive Disorder (MDD), Migraine and Alzheimer’s disease. Key programs include rapastinel (MDD) Ubrogepant (Acute Migraine), M1, M4 and M1/M4 Agonists (Alzheimer’s disease) and an NR2Br Antagonist (OCD/Autism).
Here's how it works:
ReHealth’s development efforts in anti-infectives are focused on bringing forward treatments for difficult to treat infections.
Lead programs include Ceftazidime/Avibactam, a potential treatment for hospital acquired bacteria pneumonia/ventilator acquired bacterial pneumonia.
Also we focus on Aztreonam/Avibactam, a novel treatment for gram-negative infections. ReHealth is also focused on adding new innovative programs throughout its seven therapeutic areas.
Apply for a Job with Us!
Each year we’ve got a lot of miscellaneous job offerings. See which ones are right for you!